Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 5:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 5,354 matching trials from the live ClinicalTrials.gov search.

Filters: Milwaukee, Wisconsin Clear all

Conditions: Colorectal Neoplasms
Interventions: Blood draw; Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 29
States / cities: Mobile, Alabama • Tucson, Arizona • Fresno, California + 26 more

Conditions: Crohn's Disease
Interventions: Matching Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 119
States / cities: Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more

Conditions: Acute Alcoholic Hepatitis
Interventions: ELAD System, Standard of Care (Control); Biological · Other
Lead sponsor: Vital Therapies, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Little Rock, Arkansas • Coronado, California • Palo Alto, California + 16 more

Conditions: Related Hematopoietic Stem Cell Donors
Interventions: Not listed
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Not listed
Enrollment: 1,812 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 52
States / cities: Phoenix, Arizona • San Diego, California • San Francisco, California + 44 more

Conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Asparaginase, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Filgrastim, Hydrocortisone Sodium Succinate, Ifosfamide, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisone, Radiation Therapy, Vincristine Sulfate; Drug · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 30 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 118
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 94 more

Conditions: Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Interventions: DB-OTO; Genetic
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Jacksonville, Florida + 6 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: BMS-986504, Izalontamab Brengitecan; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 10
States / cities: Anchorage, Alaska • Boston, Massachusetts • Detroit, Michigan + 6 more

Conditions: Carcinoma, Renal Cell
Interventions: Bay 59-8862; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 13
States / cities: La Jolla, California • Muncie, Indiana • New Orleans, Louisiana + 9 more

Conditions: Stroke
Interventions: Aggrenox, Clopidogrel placebo, Micardis, Aggrenox placebo, Clopidogrel, Micardis placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 20,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 204
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 160 more

Conditions: Immunoglobulin Light Chain (AL) Amyloidosis
Interventions: ABBV-383 (Etentamig); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 12
States / cities: Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Non-small Cell Lung Cancer Metastatic
Interventions: SAR408701, Docetaxel; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 8
States / cities: Fort Myers, Florida • St. Petersburg, Florida • Grand Rapids, Michigan + 5 more

Conditions: Relapsed Small Cell Lung Cancer
Interventions: Irinotecan, Lurbinectedin, Topotecan; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 15
States / cities: Chandler, Arizona • Hot Springs, Arkansas • Fort Myers, Florida + 12 more

Conditions: Sleep Hygiene, Sleep
Interventions: Sleep Hygiene tips; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Kidney Transplantation
Interventions: FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids, FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids, MMF 2 g + full-dose Neoral (FDN) + corticosteroids; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 42
States / cities: Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 36 more

Conditions: Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Questionnaire Administration, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine; Procedure · Drug · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 154
States / cities: Birmingham, Alabama • Duarte, California • Dublin, California + 127 more

Conditions: Adenomatous Polyps
Interventions: 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), placebo to 0.5 mg calcitriol (1a -25-dihydroxycholecalciferol), placebo to 75 mg acetylsalicylic acid (ASA) + 1250 mg calcium carbonate (CaCO3), Colonoscopy; Drug · Procedure
Lead sponsor: Colotech A/S; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 24
States / cities: Huntsville, Alabama • San Diego, California • Clearwater, Florida + 20 more

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Daratumumab/rHuPH20; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2040
U.S. locations: 837
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 526 more

Conditions: Prostate Cancer
Interventions: Radiation Therapy, Enzalutamide, Bicalutamide, GnRH analog; Radiation · Drug
Lead sponsor: RTOG Foundation, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 106
States / cities: Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 89 more

Conditions: Desmoplastic/Nodular Medulloblastoma, Medulloblastoma, Medulloblastoma With Extensive Nodularity, Nevoid Basal Cell Carcinoma Syndrome
Interventions: Carboplatin, Cognitive Assessment, Cyclophosphamide, Etoposide, Laboratory Biomarker Analysis, Methotrexate, Vincristine Sulfate; Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 47 Months
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 158
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 126 more

Conditions: Hemophilia A With Inhibitors
Interventions: Factor VIII concentrates, Low-dose treatment, High-dose treatment; Drug · Other
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: Up to 7 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 39
States / cities: Birmingham, Alabama • Duarte, California • Orange, California + 31 more

Conditions: Peripheral Artery Disease, Claudication, Intermittent, Vasodilation
Interventions: Red Light (670 nm energy), Octafluoropropane; Device · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Diffuse Large B Cell Lymphoma (DLBCL)
Interventions: Polatuzumab Vedotin, Mosunetuzumab, Cyclophosphamide, Doxorubicin, Prednisone, Pegfilgrastim; Drug · Other
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 70 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Bradycardia
Interventions: Micra Pacemaker Implant; Device
Lead sponsor: Medtronic; Industry
Eligibility: 18 Years and older
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 29
States / cities: Los Angeles, California • New Haven, Connecticut • Jacksonville, Florida + 25 more

Conditions: Atrial Fibrillation, Stroke, Embolism
Interventions: Rivaroxaban, Warfarin, Matching placebo for Rivaroxaban arm (Warfarin placebo), Matching placebo for Warfarin arm (Rivaroxaban placebo); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 14,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 295
States / cities: Birmingham, Alabama • Dothan, Alabama • Geneva, Alabama + 292 more

Search by objective public record fields.

Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD

Stem Cell Related Donor Safety Study

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

The Effect of Sleep Extension in Teenage Girls at a College Preparatory High School

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplant

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

Chemoprevention of Colorectal Adenomas

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

International Immune Tolerance Study

Red Light Treatment in Peripheral Artery Disease

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Micra Transcatheter Pacing System Continued Access Study Protocol

An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation